Phase 3 N=194 A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine (0462-087)
Acute Migraine
Primary: Pain Relief (PR) — 102; 21; 100; 78 attacks — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=458 Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE)
Carcinoma, Hepatocellular
Primary: Time to Progression (TTP) — 164; 112 days
Phase 3 N=528 Cetrorelix Pamoate IM Regimens in Patients With Symptomatic Benign Prostatic Hyperplasia (BPH)
Benign Prostatic Hypertrophy
Primary: IPSS Change From Baseline — -5.6 Units on a scale — p=<0.001
Phase 3 N=448 Booster Vaccination Study With a Pneumococcal Vaccine in Children Primed With the Same Vaccine
Infections, Streptococcal
Primary: Number of Subjects Reporting Grade 3 Adverse Events — 42; 13 Participants
Phase 3 N=682 The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study
Macular Edema, Cystoid · Retinal Vein Occlusion
Primary: The Number of Study Participants Experiencing an Improvement by 15 or More Letters From Baseline in Best-corrected ETDRS Visual Acuity Score at the 12-month Visit — 5…
Phase 3 N=626 Study of Topically Administered Oxybutynin Gel in Patients With Urge Incontinence
Urge Urinary Incontinence · Urinary Frequency
Primary: Change From Baseline in Mean Weekly Frequency of Urinary Incontinence Episodes at Week 12 — -24.8; -21.9; -20.0 Episodes
Phase 3 N=420 Cetrorelix Pamoate in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Benign Prostatic Hypertrophy
Primary: International Prostate Symptom Score (IPSS) — -6.2; -5.1; -5.7 Units on a scale — p=0.371
Phase 3 N=48 Efficacy of Peginterferon Alfa-2b in Previously Untreated Subjects With Chronic Hepatitis B and D Co-infection (Study P04603)
Hepatitis D, Chronic · Hepatitis B, Chronic
Primary: Number of Participants With a Virological Response — 12; 24; 9; 27 Participants
Phase 3 N=1,553 Long-Term, Open Label Atomoxetine Study
Attention Deficit Hyperactivity Disorder
Primary: Categorical Changes in Vital Signs (Blood Pressure [BP], Pulse, Weight, Temperature) During the Study — 228; 92; 19; 39 participants
Phase 3 N=184 Long-term Persistence Study to Assess a Booster Dose of GSK Biologicals' Hib-MenC
Haemophilus Influenzae Type b · Neisseria Meningitidis
Primary: Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers Equal to or Above Cut-off Value of 1:8 — 44; 93; 0…
Phase 3 N=226 A Randomized, Double-Blinded, Placebo-Controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Carcinoma, Hepatocellular
Primary: Overall Survival — 198; 127 days — p=0.014144
Phase 3 N=442 A Study Of Sunitinib In Combination With Capecitabine Compared With Capecitabine In Patients With Breast Cancer
Breast Neoplasms
Primary: Progression Free Survival (PFS) — 5.5; 5.9; 5.4; 5.5 months — p=0.9409
Phase 3 N=111 Gastrointestinal and Health-related Quality of Life Outcomes in Patients With Autoimmune Diseases Treated With Mycophenolate
Autoimmune Disease
Primary: Changes in GI Symptom Severity After Conversion From Mycophenolate Mofetil (MMF) to Enteric-coated Mycophenolate Sodium (EC-MPS) — 2.28; 2.02; -0.28 Scores on a scale
Phase 3 N=267 The Efficacy and Safety of Sildenafil Citrate Used in Combination With Intravenous Epoprostenol in PAH
Pulmonary Hypertension
Primary: Categorized Change From Baseline in 6-Minute Walking Distance — 27; 46; 20; 26 participants
Phase 3 N=128 Intensified vs. Standard Dose Therapy With Mycophenolate Sodium Plus Cyclosporin Microemulsion and Corticosteroid Combination in Patients With de Novo Renal Transplant Patients
Renal Transplantation
Primary: Time to First Occurrence of a Mycophenolic Acid (MPA) Plasma Concentration of ≥ 40 mg*h/L — 7.00; 43.00 Days